S01ED51 • dorzolamide + timolol • Sensory organs | Antiglaucoma preparations and miotics | Beta blocking agents
The combination of Dorzolamidum + Timololum is used for the treatment of glaucoma and ocular hypertension in patients who do not respond adequately to monotherapy. Dorzolamidum is a carbonic anhydrase inhibitor, and Timololum is a beta-blocker; together, they reduce intraocular pressure through complementary mechanisms.
The medication is available as eye drops and is usually administered twice daily, according to the doctor's instructions. It is effective in preventing optic nerve damage and preserving vision.
Side effects may include burning or stinging sensation in the eyes, bitter taste, dry eyes, fatigue, and, in rare cases, allergic reactions. Regular monitoring of intraocular pressure is essential.
Consult your doctor to discuss the benefits and risks of treatment with this combination. Follow the administration instructions to ensure treatment effectiveness.
Substance: dorzolamide + timolol
Date of last drug list: 01-06-2019
Commercial code: W65460002
Concentration: 20mg / 5mg / ml
Pharmaceutical form: ophthalmic drops suspension
Quantity: 2
Product type: original
Prescription restrictions: P-6L - Medicines prescription that isn't retained in the pharmacy (can be renewed); the prescription can be used for 6 months from the moment of release.
Manufacturer: SANTEN OY - FINLANDA
Holder: SANTEN OY - FINLANDA
Number: 11102/2018/02
Shelf life: 2 years-after packing for marketing;after the first opening of the bottle-2 months